Evidence map›Paper›PMID 41123704›Full record

ArticleNeurochemical research2025

Antiseizure Effects of Mirtazapine in a Rat Model of Status Epilepticus Via Cannabinoid Receptor Modulation.

Ali Vafaei, Mohammad Amin Manavi, Samaneh Toutounchian, Maedeh Mohaghegh, Razieh Mohammad Jafari, Mohammad Amin Kharaghani, Ahmad Reza Dehpour

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali Vafaei *Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Amin Manavi *Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID http://orcid.org/0000-0002-1414-9063
Samaneh ToutounchianExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maedeh MohagheghExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Razieh Mohammad JafariExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Amin KharaghaniExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ahmad Reza DehpourExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran. Dehpour@yahoo.com.ORCID http://orcid.org/0000-0002-8001-5565

Funding

Iran National Science Foundation 1401-2-209-58542
6 · The paper itself

Abstract

Status epilepticus (SE) is a severe neurological condition with high morbidity and mortality rates. Despite the availability of treatments, many cases remain refractory to standard therapies. In this study we investigated the possible anticonvulsant effects of mirtazapine in SE-induced rats, and further examined the underlying mechanisms contributing to its observed neuroprotective properties. Male Wistar rats were subjected to SE and pre-treated with different doses of mirtazapine (3, 10, 30, 50 mg/kg). Seizure severity using Racine's scale and latency of first seizure were assessed. The involvement of cannabinoid receptors was examined using AM-630, a CB2 antagonist (0.5 mg/kg). Diazepam (1 mg/kg), a GABA

Indexed as

AnticonvulsantsMirtazapineReceptors, CannabinoidStatus EpilepticusAnimalsDiazepamDisease Models, AnimalDose-Response Relationship, DrugMaleRatsRats, WistarReceptor, Cannabinoid, CB1AnticonvulsantsDiazepamMirtazapineReceptor, Cannabinoid, CB1Receptors, CannabinoidCannabinoid receptorsGABAergic systemKATP channelsKynurenine pathwayMirtazapineStatus epilepticus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.